Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Infectious Disease›Clinical Question·Updated Jul 4, 2026·v1

empiric antibiotics for community-acquired bacterial meningitis [Grok-4.3]

The [[Tuberculous Meningitis]] International Research Consortium guideline provides evidence-based recommendations for optimal treatment and diagnosis of tuberculous meningitis but does not address community-acquired bacterial meningitis [1]. Very low-certainty evidence from three prospective cohort studies indicates an uncertain effect of early versus delayed empiric antimicrobial treatment

Moderate Evidence19 references·1,048 words·5 min read·v1
The [[Tuberculous Meningitis]] International Research Consortium guideline provides evidence-based recommendations for optimal treatment and diagnosis of tuberculous meningitis but does not address community-acquired bacterial meningitis [1]. Very low-certainty evidence from three prospective cohort studies indicates an uncertain effect of early versus delayed empiric antimicrobial treatment on all-cause mortality in suspected acute meningitis (RR 0.41, 95% CI 0.26-0.65) [9] (NNT not calculable from reported data).

Board Review — High Yield

  • •Guideline [1] supplies TBM recommendations only, with no CABM content
  • •Meta-analysis of three cohort studies (601 participants) linked early empiric antimicrobials to lower mortality (RR 0.41) in suspected acute meningitis [9]
  • •Very low-certainty evidence indicates uncertain mortality reduction with early empiric antimicrobials (RR 0.41, 95% CI 0.26-0.65) [9].
  • •Most data derive from tuberculous meningitis cohorts, creating high indirectness for pyogenic community-acquired bacterial meningitis in adults.
  • •Rickettsia typhi and Rickettsia prowazekii can mimic community-acquired bacterial meningitis and warrant empiric doxycycline in endemic areas [17].

Deep Dive — Evidence Details

References

  1. [1]

    Donovan J, Cresswell FV, Tucker EW et al.. “A clinical practice guideline for tuberculous meningitis.” The Lancet. Infectious diseases (2025). PMID: 40840485 ↗

    L2GUIDELINECited in: Bottom Line
  2. [2]

    Pu J, Wu S, He JQ. “High dose of rifampicin in the treatment of tuberculous meningitis: a systematic review and meta-analysis of randomized controlled trials.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41511673 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  3. [3]

    Huang M, Wang Y, Chen T et al.. “Evaluation of contezolid's cerebrospinal fluid concentration and safety in tuberculous meningitis patients.” Microbiology spectrum (2026). PMID: 41823550 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  4. [4]

    Donovan J, Duc Bang N, Dong HKT et al.. “Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.” Nature medicine (2026). PMID: 41540106 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  5. [5]

    Chandu M, Bhatia R, Modi M et al.. “Patterns and Factors Associated With Cerebral Infarction on MRI in Tuberculous Meningitis: Secondary Analysis of the ACT-TBM Trial.” Stroke (2026). PMID: 41521897 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  6. [6]

    Donovan J, Thanh NT, Ngoc LHB et al.. “The cause, treatment and outcome of hyponatraemia associated with tuberculous meningitis: An observational study nested within two clinical trials of corticosteroids.” The Journal of infection (2026). PMID: 42167495 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  7. [7]

    Nasiri MJ, Hamzelouee G, Rezaeinasab M et al.. “A systematic review and meta-analysis of steroid use for treatment of TB meningitis.” The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease (2026). PMID: 42374702 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  8. [8]

    Prasad M, Kumar A, Couban R et al.. “Duration of anti-seizure medicines started for acute symptomatic seizures due to acute meningitis: a systematic review and meta-analysis.” BMC medicine (2026). PMID: 42021346 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  9. [9]

    Thampy A, Alexander H, John JM et al.. “Early vs. delayed empiric antimicrobial treatment for suspected acute meningitis - a systematic review and meta-analysis.” BMC infectious diseases (2026). PMID: 41688940 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  10. [10]

    Lazarus G, Caddey B, Dean A et al.. “Antimicrobial resistance in bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae (2010-24): a systematic review and meta-analysis.” The Lancet. Microbe (2026). PMID: 41616789 ↗

    L2SR_OBSCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  11. [11]

    Duffy N, Koirala A, Williams PCM. “Epidemiology and Outcomes of Culture-proven Neonatal Meningitis in Australian Tertiary Hospitals: A Multicenter Retrospective Cohort Study.” The Pediatric infectious disease journal (2026). PMID: 41543078 ↗

    L3COHORTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  12. [12]

    Giriappa B, Choraria N, Ponce P et al.. “Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.” Human vaccines & immunotherapeutics (2026). PMID: 41504209 ↗

    L2TRIAL_NONRANDOMCited in: Current Evidence and Standard, On the Horizon
  13. [13]

    Luan M, Chen X. “Efficacy and safety of drug therapies for treating tuberculous meningitis: a network meta-analysis.” Journal of infection in developing countries (2026). PMID: 42112729 ↗

    L2SR_OBSCited in: Current Evidence and Standard
  14. [14]

    Hodgson A, Haidara FC, Sow SO et al.. “Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.” Vaccine (2025). PMID: 40966979 ↗

    L1RCTCited in: On the Horizon
  15. [15]

    Diallo F, Haidara FC, Tapia MD et al.. “Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.” Lancet (London, England) (2025). PMID: 40086461 ↗

    L1RCTCited in: On the Horizon
  16. [16]

    Huynh J, Chabala C, Sharma S et al.. “Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis.” BMJ open (2025). PMID: 40180374 ↗

    L2TRIAL_NONRANDOMCited in: On the Horizon
  17. [17]

    Roxas PB, Cruz J, Horelka NR et al.. “Typhus group Rickettsia community-acquired bacterial central nervous system infections: We must think outside the box!” Journal of the neurological sciences (2024). PMID: 39447222 ↗

    L2SR_OBSCited in: On the Horizon
  18. [18]

    Petersen PT, Bodilsen J, Jepsen MPG et al.. “Dexamethasone in adults with viral meningitis: an observational cohort study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024). PMID: 39182578 ↗

    L3COHORTCited in: On the Horizon
  19. [19]

    Begum S, Herrera-Restrepo O, Rolland C et al.. “Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review.” Human vaccines & immunotherapeutics (2024). PMID: 39373020 ↗

    L2SR_OBSCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…